Literature DB >> 22684314

Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society.

Maurizio Soresi1, Davide Noto, Angelo B Cefalù, Scipione Martini, Giovanni Battista Vigna, Maurizio Fonda, Enzo Manzato, Luigi Cattin, Renato Fellin, Maurizio R Averna, Alberto Notarbartolo.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is associated with all the components of metabolic syndrome (MS) and might to be considered an additional component of MS itself. The Italian Society for the Study of Atherosclerosis (SISA) in 2005 started a research project aimed to study the NAFLD, using ultrasound (US), in nondiabetic MS subjects matching at least one of the ATP III criteria for HDL-C or triglycerides [TG]. Prevalence of US-NAFLD and its associated risk factors and prevalence of hypertransaminasemia and its possible determinants were evaluated. NAFLD prevalence was 0.78. Men with steatosis compared to men without steatosis were younger (P < 0.05) with higher TG (P < 0.03), homeostasis model assessment insulin resistance (HOMA-R) (P < 0.003), and visceral fat thickness (VFT) (P < 0.0001). Women with steatosis showed higher TG (P < 0.05), HOMA-R (P < 0.04), VFT (P < 0.0001), and lower age (P < 0.05). At multivariate analyses, VFT (P < 0.0001), HOMA-R (P < 0.02), and TG/HDL (P < 0.05) were associated with severity of NAFLD. Age (P < 0.05), LogTG (P < 0.005), and VFT (P < 0.01) were associated with higher ALT. The US prevalence of steatosis in this study (0.78) is the highest reported in patients with MS. Considering the exclusion of severe obese and diabetic patients and the recruitment criteria, this finding highlights the prominent role played by the alterations of lipid metabolism in the pathogenesis of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684314     DOI: 10.1007/s00592-012-0406-1

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  16 in total

1.  Non invasive tools for the diagnosis of liver cirrhosis.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Melchiorre Cervello; Anna Licata; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

2.  Pancreatic cancer: risk and preventive factors.

Authors:  Anna Licata; Giuseppe Montalto; Maurizio Soresi
Journal:  Intern Emerg Med       Date:  2018-02-07       Impact factor: 3.397

Review 3.  Nonalcoholic fatty liver disease and aging: epidemiology to management.

Authors:  Marco Bertolotti; Amedeo Lonardo; Chiara Mussi; Enrica Baldelli; Elisa Pellegrini; Stefano Ballestri; Dante Romagnoli; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 4.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

5.  Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults.

Authors:  Haijiang Dai; Weijun Wang; Ruifang Chen; Zhiheng Chen; Yao Lu; Hong Yuan
Journal:  Nutr Metab (Lond)       Date:  2017-08-01       Impact factor: 4.169

6.  Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns.

Authors:  Maurizio Soresi; Antonino Terranova; Anna Licata; Antonietta Serruto; Giuseppe Montalto; Giuseppe Brancatelli; Lydia Giannitrapani
Journal:  Biomed Res Int       Date:  2017-05-30       Impact factor: 3.411

7.  The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods.

Authors:  Maurizio Soresi; Daniela Cabibi; Rosaria V Giglio; Stefania Martorana; Giuseppina Guercio; Rossana Porcasi; Antonino Terranova; Luigi A Lazzaro; Maria R Emma; Giuseppa Augello; Melchiorre Cervello; Gianni Pantuso; Giuseppe Montalto; Lydia Giannitrapani
Journal:  Biomed Res Int       Date:  2020-04-26       Impact factor: 3.411

8.  Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Maria Nadinskaia; Marina Maevskaya; Vladimir Ivashkin; Khava Kodzoeva; Irina Pirogova; Evgeny Chesnokov; Alexander Nersesov; Jamilya Kaibullayeva; Akzhan Konysbekova; Aigul Raissova; Feruza Khamrabaeva; Elena Zueva
Journal:  World J Gastroenterol       Date:  2021-03-14       Impact factor: 5.742

9.  Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis.

Authors:  Evangelos Cholongitas; Ioanna Pavlopoulou; Margarita Papatheodoridi; George E Markakis; Emmanouil Bouras; Anna-Bettina Haidich; George Papatheodoridis
Journal:  Ann Gastroenterol       Date:  2021-02-26

10.  Nonalcoholic Fatty Liver Disease Aggravated the Severity of Acute Pancreatitis in Patients.

Authors:  Dacheng Wu; Min Zhang; Songxin Xu; Keyan Wu; Ningzhi Wang; Yuanzhi Wang; Jian Wu; Guotao Lu; Weijuan Gong; Yanbing Ding; Weiming Xiao
Journal:  Biomed Res Int       Date:  2019-01-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.